

### Remarks

In the specification, SEQ ID NOs: 4-22 have been renumbered as SEQ ID NOs: 3-21, respectively. Specifically, SEQ ID NOs: 17-21 in Table 4 have been changed to SEQ ID NOs: 16-20, respectively. SEQ ID NOs: 16, 17, and 22 in the paragraph beginning at page 11, line 31, have been changed to SEQ ID NOs: 15, 16, and 21, respectively. SEQ ID NOs: 4-15 in Examples 2-13 have been renumbered as SEQ ID NOs: 3-14, respectively.

Claims 1-53 are pending. By this amendment, claim 18 has been amended to correct a minor typographic error. In addition, the term "SEQ ID NO:22" in claim 18 has been changed to "SEQ ID NO:21" in order to be consistent with the amendments to the specification. Likewise, the term "SEQ ID NO:16" in claim 20 has been replaced with "SEQ ID NO:15."


Moreover, Applicants have submitted herewith a paper copy and a computer readable form (CRF) of the Sequence Listing which includes SEQ ID NOs: 1-21. The content in the CRF is identical to the paper copy of the Sequence Listing.

The amendments to the specification, claims, and Sequence Listing do not introduce new matter. Accordingly, entry of these amendments is respectfully requested.

Applicants respectfully request that a timely Notice of Allowance be issued in this case. Should the Examiner have any questions, the Examiner is invited to contact Applicants' representative designated below.

Date: February 2, 2005

Respectfully submitted,



Raymond Van Dyke  
Reg. No. 34,746

Nixon Peabody LLP  
Suite 900  
401 9<sup>th</sup> Street  
Washington D.C. 2004-2128  
Tel: (202) 585-8250  
Fax: (202) 585-8080